Denali Therapeutics/$DNLI
1D1W1MYTD1Y5YMAX
Capital at risk
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
- Ticker
- $DNLI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 503
- Headquarters
- South San Francisco, United States
- Website
- www.denalitherapeutics.com
DNLI Metrics
BasicAdvanced
$3.2B
-
-$2.83
1.00
-
Price and volume
Market cap
$3.2B
Beta
1
52-week high
$27.30
52-week low
$12.58
Average daily volume
1.3M
Financial strength
Current ratio
8.369
Quick ratio
7.947
Long term debt to equity
0.033
Total debt to equity
0.045
Profitability
EBITDA (TTM)
-526.058
Gross margin (TTM)
-11,021.34%
Net profit margin (TTM)
-14,191.20%
Operating margin (TTM)
-15,037.38%
Effective tax rate (TTM)
-0.02%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-29.15%
Return on equity (TTM)
-54.93%
Valuation
Price to revenue (TTM)
1,008.012
Price to book
3.85
Price to tangible book (TTM)
4.02
Price to free cash flow (TTM)
-7.792
Free cash flow yield (TTM)
-12.83%
Free cash flow per share (TTM)
-2.584
Growth
Earnings per share change (TTM)
0.92%
3-year revenue growth (CAGR)
-78.10%
3-year earnings per share growth (CAGR)
42.85%
What the Analysts think about DNLI
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
Analyst projections of the future price of Denali Therapeutics stock.
Bulls say / Bears say
AVLAYAH generated $3.6 million in its first full commercial quarter, and Denali guided to $10 million–$12 million in the following quarter as payer coverage expands. That gives the company an early revenue base and a near-term test of launch momentum. (GlobeNewswire, Denali Therapeutics 10-Q)
Denali has moved two TransportVehicle-enabled Alzheimer’s programmes into clinical development: DNL628 targets tau and DNL921 targets amyloid beta. Their 2027 biomarker and proof-of-concept readouts could show whether the brain-delivery platform works beyond rare diseases and materially broaden the opportunity. (GlobeNewswire, The Motley Fool)
Pro forma cash, cash equivalents and marketable securities exceeded $1.1 billion after Denali sold its priority review voucher for $195 million. This provides funding to commercialise AVLAYAH, prepare the potential 2027 launch of zafinofusp alfa and advance several clinical programmes without an immediate need for new equity. (GlobeNewswire, The Motley Fool)
DNL151 failed to slow Parkinson’s progression in the Phase 2b LUMA study, missing both its primary and secondary endpoints. Denali and Biogen stopped development in idiopathic Parkinson’s disease, leaving only a narrower genetically selected study as a remaining opportunity for the programme. (Biogen, GlobeNewswire)
Takeda terminated its collaboration on DNL593, returning full control of the programme to Denali, and the expected readout was pushed into the first half of 2027. Denali says the exit was strategic rather than data-driven, but losing a major partner increases execution and funding responsibility for a small biotech. (GlobeNewswire, The Motley Fool)
The company remains loss-making: second-quarter net loss was $127.6 million against just $3.6 million of AVLAYAH revenue. Commercial costs are rising while most of the pipeline is still unproven, so Denali needs a sustained product ramp or successful clinical readouts to justify its ongoing cash consumption. (Denali Therapeutics 10-Q, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
DNLI Financial Performance
Revenues and expenses
DNLI Earnings Performance
Company profitability
Upcoming events
No upcoming events
DNLI News
AllArticlesVideos
Funds containing DNLI
AllUSDGBPEUR
Fund name | Fund size | $DNLI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.21% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.21% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.